MPLT Stock: MapLight Therapeutics, Inc. Stock Price, Analysis & Insights
Get live mplt stock price $16.63, comprehensive MapLight Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time mplt stock data and investment insights.
Loading chart...
Company Overview
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
Company Information
- CEO
- Christopher A. Kroeger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
Contact Information
- Website
- https://www.maplightrx.com
- Address
- 800 Chesapeake Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.00) may provide portfolio stability
Business Model & Strategy
MapLight Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Christopher A. Kroeger, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
MapLight Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 13.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, MapLight Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating MapLight Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for MapLight Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for MapLight Therapeutics, Inc.
- ⚠Investors should consider how MapLight Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
13.13M
P/E Ratio
-7.46
Beta
0.00
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 13.13M market capitalization
- Trading Volume: 547.30K shares traded today
- Price Range: 52-week range of $12.24 - $20.86
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. (MPLT) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 13.13M, the company represents a significant player in its market. The stock is currently trading at $16.63 with a positivedaily change of 29.01%.
The company's 109 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -7.46, beta of 0.00, and 52-week price range from $12.24 to $20.86when evaluating investment opportunities.
Why Invest in MapLight Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Christopher A. Kroeger
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.